In 2019, the Neuronet Sessions introduced the projects of the Innovative Medicines Initiative (IMI) neurodegeneration portfolio to a broad audience composed of people with dementia, caregivers, patient associations, researchers and clinicians. This year, Neuronet is expanding the focus of its public event, which will be held as part of the Alzheimer Europe annual conference between 20-22 October.
Neuronet is an IMI-funded coordination and support action designed to act as a key enabler and mediator for the IMI neurodegeneration portfolio, which includes projects such as EPAD, PHAGO, ROADMAP and ADAPTED among others. During the 2020 Neuronet Sessions, IMI project collaborators will present their work on data sharing, ethics and regulatory interactions. In a Roundtable session, IMI project leaders will address the challenges experienced by public-private partnerships during the COVID-19 pandemic, discussing how research will evolve in the critical post-COVID period.
Neuronet is also dedicating a session to early-career researchers (ECRs) working on IMI projects, designed to showcase the breadth and depth of IMI-funded neurodegeneration research as well as the diversity of project collaborators involved. All ECRs (defined as graduate students or researchers within 10 years of completing their graduate studies) working on the 18 projects in the IMI neurodegeneration portfolio are invited to submit abstracts via the online abstract submission portal.
